Logo image of ARYD

ARYA SCIENCES ACQUISITION-A (ARYD) Stock Fundamental Analysis

NASDAQ:ARYD - Nasdaq - KYG316591083 - Common Stock - Currency: USD

6.64  -2.32 (-25.92%)

After market: 8 +1.36 (+20.48%)

Fundamental Rating

0

We assign a fundamental rating of 0 out of 10 to ARYD. ARYD was compared to 0 industry peers in the Unkown industry. ARYD has a bad profitability rating. Also its financial health evaluation is rather negative. ARYD does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year ARYD has reported negative net income.
In the past year ARYD has reported a negative cash flow from operations.
ARYD Yearly Net Income VS EBIT VS OCF VS FCFARYD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 0 -2M -4M -6M

1.2 Ratios

Industry RankSector Rank
ROA -6.83%
ROE -11.32%
ROIC N/A
ROA(3y)-2.97%
ROA(5y)N/A
ROE(3y)-4.09%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ARYD Yearly ROA, ROE, ROICARYD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 0 -2 -4 -6 -8 -10

1.3 Margins

ARYD does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ARYD Yearly Profit, Operating, Gross MarginsARYD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023

More info and screens

1

2. Health

2.1 Basic Checks

ARYD has less shares outstanding than it did 1 year ago.
The debt/assets ratio for ARYD is higher compared to a year ago.
ARYD Yearly Shares OutstandingARYD Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 5M 10M 15M
ARYD Yearly Total Debt VS Total AssetsARYD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 50M 100M 150M

2.2 Solvency

ARYD has an Altman-Z score of 0.69. This is a bad value and indicates that ARYD is not financially healthy and even has some risk of bankruptcy.
A Debt/Equity ratio of 0.14 indicates that ARYD is not too dependend on debt financing.
Industry RankSector Rank
Debt/Equity 0.14
Debt/FCF N/A
Altman-Z 0.69
ROIC/WACCN/A
WACCN/A
ARYD Yearly LT Debt VS Equity VS FCFARYD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 0 50M 100M

2.3 Liquidity

ARYD has a Current Ratio of 0.01. This is a bad value and indicates that ARYD is not financially healthy enough and could expect problems in meeting its short term obligations.
A Quick Ratio of 0.01 indicates that ARYD may have some problems paying its short term obligations.
Industry RankSector Rank
Current Ratio 0.01
Quick Ratio 0.01
ARYD Yearly Current Assets VS Current LiabilitesARYD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2M 4M 6M 8M 10M

More info and screens

0

3. Growth

3.1 Past

ARYD shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -306.97%.
EPS 1Y (TTM)-306.97%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-263.1%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ARYD Yearly Revenue VS EstimatesARYD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023
ARYD Yearly EPS VS EstimatesARYD Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ARYD. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ARYD Price Earnings VS Forward Price EarningsARYD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ARYD Per share dataARYD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

ARYD does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ARYA SCIENCES ACQUISITION-A

NASDAQ:ARYD (7/31/2024, 8:22:11 PM)

After market: 8 +1.36 (+20.48%)

6.64

-2.32 (-25.92%)

Chartmill FA Rating
GICS SectorN/A
GICS IndustryGroupN/A
GICS IndustryN/A
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners1.15%
Inst Owner Change0%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap50.07M
Analysts0
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.23
P/tB 2.23
EV/EBITDA N/A
EPS(TTM)-0.19
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.14
FCFYN/A
OCF(TTM)-0.14
OCFYN/A
SpS0
BVpS2.98
TBVpS2.98
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -6.83%
ROE -11.32%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-2.97%
ROA(5y)N/A
ROE(3y)-4.09%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.14
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.01
Quick Ratio 0.01
Altman-Z 0.69
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-306.97%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-263.1%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-155.63%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-163.47%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-163.47%
OCF growth 3YN/A
OCF growth 5YN/A